By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem webinar on large-scale MCSGP purification
Bubendorf, Switzerland: – The leading CDMO for peptides and oligonucleotides manufacturing, Bachem’s latest online webinar will focus on use of Multicolumn Counter-current Solvent Gradient Purification (MCSGP) to process large synthetic peptide and oligomer molecules.
Bachem acquired its first two process-scale MCSGP systems in 2021 for the purification of peptides and oligonucleotides. Its systems are qualified for GMP use and have been used to that level for purifications at industrial scale.
Progress to large scale MCSGP
The webinar will trace Bachem’s progress in establishing large-scale MCSGP, starting from initial small-scale experiments in 2017 to the first large-scale API purification earlier this year.
Besides sharing real data from process development and manufacturing, the discussion will provide insights regarding potential control strategies as well as the general workflow for process-scale MCSGP purification of large synthetic molecules.
The event will be hosted online via the Zoom platform on November 10, 2022, commencing at 1720 hrs. EDT (UTC +2) and lasting approximately 70 minutes. Registration for the event is free of charge and can be completed online (see Resources).
Principle speaker for the session will be Bachem’s Process Manager for Chromatography and Technology Transfer Oligo, Ralf Eisenhuth.
Ralf joined Bachem AG in 2008. Over the last decade, he held several positions at Bachem: ranging from process development to leading the large-scale purification of peptides at the Bubendorf site. In his current position as Process Manager Chromatography and Technology Transfer, he is focusing on innovative purification technologies and processes.
The session will also feature contributions from the USA by Bachem Business Development Manager Keith Porter, who has more than ten years of research and development experience in the field of solid-phase peptide synthesis (SPPS) and spent most of his career striving to improve this technique.
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
For further information, see www.bachem.com.
Click on Bachem webinar ‘Process-scale MCSGP purification of large synthetic molecules’ to register for the event.
Click on Bachems News to see latest News & Events.